vs
Side-by-side financial comparison of HERTZ GLOBAL HOLDINGS, INC (HTZ) and Jazz Pharmaceuticals plc (JAZZ). Click either name above to swap in a different company.
HERTZ GLOBAL HOLDINGS, INC is the larger business by last-quarter revenue ($2.0B vs $1.2B, roughly 1.7× Jazz Pharmaceuticals plc). Jazz Pharmaceuticals plc runs the higher net margin — 17.0% vs -16.6%, a 33.6% gap on every dollar of revenue. On growth, HERTZ GLOBAL HOLDINGS, INC posted the faster year-over-year revenue change (11.0% vs 10.1%). Over the past eight quarters, Jazz Pharmaceuticals plc's revenue compounded faster (15.2% CAGR vs -7.7%).
Hertz Global Holdings, Inc., known as Hertz, is an American car rental company based in Estero, Florida. The company operates its namesake Hertz brand, along with the brands Dollar Rent A Car, Firefly Car Rental, and Thrifty Car Rental.
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
HTZ vs JAZZ — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.0B | $1.2B |
| Net Profit | $-333.0M | $203.5M |
| Gross Margin | — | — |
| Operating Margin | — | 21.2% |
| Net Margin | -16.6% | 17.0% |
| Revenue YoY | 11.0% | 10.1% |
| Net Profit YoY | 24.8% | 6.5% |
| EPS (diluted) | $-1.06 | $3.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $2.0B | — | ||
| Q4 25 | $2.0B | $1.2B | ||
| Q3 25 | $2.5B | $1.1B | ||
| Q2 25 | $2.2B | $1.0B | ||
| Q1 25 | $1.8B | $897.8M | ||
| Q4 24 | $2.0B | $1.1B | ||
| Q3 24 | $2.6B | $1.1B | ||
| Q2 24 | $2.4B | $1.0B |
| Q1 26 | $-333.0M | — | ||
| Q4 25 | $-194.0M | $203.5M | ||
| Q3 25 | $184.0M | $251.4M | ||
| Q2 25 | $-294.0M | $-718.5M | ||
| Q1 25 | $-443.0M | $-92.5M | ||
| Q4 24 | $-479.0M | $191.1M | ||
| Q3 24 | $-1.3B | $215.1M | ||
| Q2 24 | $-865.0M | $168.6M |
| Q1 26 | — | — | ||
| Q4 25 | -11.0% | 21.2% | ||
| Q3 25 | 9.4% | 5.1% | ||
| Q2 25 | -14.5% | -65.6% | ||
| Q1 25 | -29.0% | -6.2% | ||
| Q4 24 | -27.6% | 17.5% | ||
| Q3 24 | -62.9% | 24.7% | ||
| Q2 24 | -20.1% | 19.5% |
| Q1 26 | -16.6% | — | ||
| Q4 25 | -9.6% | 17.0% | ||
| Q3 25 | 7.4% | 22.3% | ||
| Q2 25 | -13.5% | -68.7% | ||
| Q1 25 | -24.4% | -10.3% | ||
| Q4 24 | -23.5% | 17.6% | ||
| Q3 24 | -51.7% | 20.4% | ||
| Q2 24 | -36.8% | 16.5% |
| Q1 26 | $-1.06 | — | ||
| Q4 25 | $-0.46 | $3.34 | ||
| Q3 25 | $0.42 | $4.08 | ||
| Q2 25 | $-0.95 | $-11.74 | ||
| Q1 25 | $-1.44 | $-1.52 | ||
| Q4 24 | $-1.57 | $2.97 | ||
| Q3 24 | $-4.34 | $3.42 | ||
| Q2 24 | $-2.82 | $2.49 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $583.0M | $1.4B |
| Total DebtLower is stronger | — | $5.4B |
| Stockholders' EquityBook value | — | $4.3B |
| Total Assets | $23.3B | $11.7B |
| Debt / EquityLower = less leverage | — | 1.24× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $583.0M | — | ||
| Q4 25 | $565.0M | $1.4B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $503.0M | $1.2B | ||
| Q1 25 | $626.0M | $1.9B | ||
| Q4 24 | $592.0M | $2.4B | ||
| Q3 24 | $501.0M | $2.2B | ||
| Q2 24 | $568.0M | $1.4B |
| Q1 26 | — | — | ||
| Q4 25 | — | $5.4B | ||
| Q3 25 | — | $5.4B | ||
| Q2 25 | — | $5.4B | ||
| Q1 25 | — | $5.4B | ||
| Q4 24 | — | $6.1B | ||
| Q3 24 | — | $6.1B | ||
| Q2 24 | — | $5.7B |
| Q1 26 | — | — | ||
| Q4 25 | $-459.0M | $4.3B | ||
| Q3 25 | $-317.0M | $4.0B | ||
| Q2 25 | $-504.0M | $3.7B | ||
| Q1 25 | $-262.0M | $4.2B | ||
| Q4 24 | $153.0M | $4.1B | ||
| Q3 24 | $681.0M | $4.2B | ||
| Q2 24 | $2.0B | $3.8B |
| Q1 26 | $23.3B | — | ||
| Q4 25 | $22.3B | $11.7B | ||
| Q3 25 | $23.0B | $11.4B | ||
| Q2 25 | $23.1B | $10.9B | ||
| Q1 25 | $22.0B | $11.5B | ||
| Q4 24 | $21.8B | $12.0B | ||
| Q3 24 | $23.0B | $12.3B | ||
| Q2 24 | $25.2B | $11.4B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.24× | ||
| Q3 25 | — | 1.35× | ||
| Q2 25 | — | 1.45× | ||
| Q1 25 | — | 1.29× | ||
| Q4 24 | — | 1.49× | ||
| Q3 24 | — | 1.47× | ||
| Q2 24 | — | 1.52× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $362.5M |
| Free Cash FlowOCF − Capex | — | $345.8M |
| FCF MarginFCF / Revenue | — | 28.9% |
| Capex IntensityCapex / Revenue | 53.6% | 1.4% |
| Cash ConversionOCF / Net Profit | — | 1.78× |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.3B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $193.0M | $362.5M | ||
| Q3 25 | $835.0M | $474.6M | ||
| Q2 25 | $346.0M | $88.9M | ||
| Q1 25 | $251.0M | $429.8M | ||
| Q4 24 | $414.0M | $398.6M | ||
| Q3 24 | $894.0M | $398.7M | ||
| Q2 24 | $546.0M | $331.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $345.8M | ||
| Q3 25 | — | $459.4M | ||
| Q2 25 | — | $75.9M | ||
| Q1 25 | — | $415.9M | ||
| Q4 24 | — | $385.3M | ||
| Q3 24 | — | $388.0M | ||
| Q2 24 | — | $324.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 28.9% | ||
| Q3 25 | — | 40.8% | ||
| Q2 25 | — | 7.3% | ||
| Q1 25 | — | 46.3% | ||
| Q4 24 | — | 35.4% | ||
| Q3 24 | — | 36.8% | ||
| Q2 24 | — | 31.7% |
| Q1 26 | 53.6% | — | ||
| Q4 25 | — | 1.4% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 1.2% | ||
| Q3 24 | — | 1.0% | ||
| Q2 24 | — | 0.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.78× | ||
| Q3 25 | 4.54× | 1.89× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.09× | ||
| Q3 24 | — | 1.85× | ||
| Q2 24 | — | 1.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HTZ
Segment breakdown not available.
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
